PharmaShots | Incisive News in 3 Shots

Subscribe Now

immunitybio

The EMA Accepts MAA for ImmunityBio’s Anktiva to Treat BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

The EMA Accepts MAA for ImmunityBio’s Anktiva to Treat BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

January 29, 2025

ImmunityBio’s Anktiva Receives the US FDA’s Approval to Treat Non-Muscle Invasive Bladder Cancer (NMIBC)

ImmunityBio’s Anktiva Receives the US FDA’s Approval to Treat Non-Muscle Invasive Bladder Cancer (NMIBC)

April 22, 2024

ImmunityBio Reports P-II/III (QUILT 3.032) Trial Results of N-803 + BCG for the Treatment of Bladder Cancer

ImmunityBio Reports P-II/III (QUILT 3.032) Trial Results of N-803 + BCG for the Treatment of Bladder Cancer

November 11, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us